| Name | JNJ-18038683 |
| Description | JNJ-18038683 is a 5-Hydroxytryptamine Type 7 (5-HT7) receptor antagonist with pKis of 8.19 and 8.20 for rat and human 5-HT7 in HEK293 cells, respectively. |
| In vitro | JNJ-18038683 produces a concentration-dependent decrease of 5-HT (100 nM)-stimulated adenylyl cyclase. The pKB values determined for JNJ-18038683 are in good agreement with the corresponding Ki values determined from [3H]5-CT binding studies.JNJ-18038683 displaced, with high affinity, specific [3H]5-CT binding sites from rat and human 5-HT7 receptor express in HEK293 cells (pKi=8.19±0.02 and 8.20±0.01, respectively). Similar values are obtained on the native 5-HT7 in membranes from rat thalamus (pKi=8.50±0.20). Hill slope values are close to unity, suggesting one-site competitive binding. Antagonist potency of JNJ-18038683 is determined by the measurement of adenylate cyclase activity in HEK293 cells expressing the human or rat 5-HT7 receptor. 5-HT stimulates adenylyl cyclase activity in rat and human 5-HT7/HEK293 cells with a pEC50 of 8.09 and 8.12, respectively. |
| In vivo | JNJ-18038683 dose-dependently reduces REM sleep, particularly within the first 4 hours post-administration, with a significant decrease observed from a dosage of 1 mg/kg (P<0.05). Furthermore, it extends REM sleep latency, showing a significant prolongation at the highest dose tested (10 mg/kg; P<0.05), indicating that these effects are specific to the REM sleep state. An additional study evaluated the impact of administering JNJ-18038683 daily for 7 days (1 mg/kg s.c. per day) on EEG sleep patterns in rats, focusing on REM sleep both during treatment and after its cessation. Initial treatment significantly reduced REM sleep duration in the first 8 hours and increased REM latency, which remained elevated throughout the 7-day treatment but returned to normal after treatment stopped. While the reduction in REM sleep persisted during the treatment period, a rebound increase in REM sleep occurred upon treatment discontinuation. Neither the latency nor the total time of NREM sleep was impacted over the treatment course. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (9.43 mM), Sonication is recommended.
DMSO : 200 mg/mL (377.38 mM), Sonication is recommended.
|
| Keywords | Serotonin Receptor | Rat 5-HT7 Receptor | JNJ-18038683 | JNJ18038683 | JNJ 18038683 | Inhibitor | inhibit | Human 5-HT7 Receptor | 5-hydroxytryptamine Receptor | 5HTReceptor | 5-HT Receptor | 5HT Receptor |
| Inhibitors Related | Alverine citrate | Olanzapine | Dapoxetine hydrochloride | Clozapine N-Oxide | Mirtazapine | D-Menthol | Amitriptyline hydrochloride | Cloperastine hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride | Fluoxetine hydrochloride | Cinchonidine |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Anti-Alzheimer's Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
